Who are Rocuronium bolus maintenance's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Succinylcholine Chloride, nicotine nasal spray, Succinylcholine + Neostigmine, Galantamine-CR, Rocuronium or Vecuronium, Nicotine gum (C).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rocuronium-bolus-maintenance.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rocuronium bolus maintenance — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rocuronium bolus maintenance (Rocuronium bolus maintenance) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-depolarizing neuromuscular blocker. Area: Anesthesiology.

phase 3 Non-depolarizing neuromuscular blocker Nicotinic acetylcholine receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Rocuronium bolus maintenance (Rocuronium bolus maintenance) — Merck Sharp & Dohme LLC. Rocuronium acts as a competitive antagonist at the nicotinic acetylcholine receptor, preventing acetylcholine from binding and thereby inhibiting muscle contraction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rocuronium bolus maintenance TARGET	Rocuronium bolus maintenance	Merck Sharp & Dohme LLC	phase 3	Non-depolarizing neuromuscular blocker	Nicotinic acetylcholine receptor
Succinylcholine Chloride	SUXAMETHONIUM	Novartis	marketed	Depolarizing Neuromuscular Blocker	Muscle-type nicotinic acetylcholine receptor	1952-01-01
nicotine nasal spray	nicotine nasal spray	Heinrich-Heine University, Duesseldorf	marketed	Nicotinic receptor agonist	Nicotinic acetylcholine receptors
Succinylcholine + Neostigmine	Succinylcholine + Neostigmine	Brno University Hospital	marketed	Neuromuscular blocking agent reversal combination	Nicotinic acetylcholine receptor; acetylcholinesterase
Galantamine-CR	Galantamine-CR	Massachusetts General Hospital	marketed	Cholinesterase inhibitor with nicotinic receptor allosteric modulator	Acetylcholinesterase; nicotinic acetylcholine receptors
Rocuronium or Vecuronium	Rocuronium or Vecuronium	Merck Sharp & Dohme LLC	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction
Nicotine gum (C)	Nicotine gum (C)	22nd Century Group, Inc.	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-depolarizing neuromuscular blocker class)

Merck Sharp & Dohme LLC · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rocuronium bolus maintenance — Competitive Intelligence Brief. https://druglandscape.com/ci/rocuronium-bolus-maintenance. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing